CLYM earnings date and last-quarter result: last quarter beat, P/E -16.13. Updated 2026-07-23.
Climb Bio (CLYM) Research Hub
Climb Bio (CLYM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 8.81 USD (-13.54%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -16.13, market cap 0.85B. This hub links to the full technical, earnings and options research available for CLYM.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.81 USD (-13.54%) |
| 52-week range | 8.7 USD – 18.33 USD |
| Trend regime | Range |
| 14-day RSI | 34.5 (Bearish) |
| Trailing P/E | -16.13 |
| Market cap | 0.85B |
| Dividend yield | 0.00% |
Available research for CLYM
Covered Call on CLYM: how it works, illustrative setup around the real 8.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CLYM: how it works, illustrative setup around the real 8.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CLYM: how it works, illustrative setup around the real 8.81 USD price, max profit/loss, breakeven and when to use it. Educational.
CLYM technical analysis: range, last 8.81 USD, RSI 34.5, 52w range 8.7 USD–18.33 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CLYM in?
Climb Bio (CLYM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CLYM in an uptrend or downtrend?
As of 2026-10-26, CLYM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CLYM's trailing P/E ratio?
CLYM's trailing P/E is -16.13, with a market cap of 0.85B. See the earnings research page for full valuation detail.